IMMUNOHISTOCHEMISTRY, CD 23

The Immunohistochemistry (IHC) – CD23 test is a specialized diagnostic test used to detect CD23 protein expression in tissue samples. CD23 is a low-affinity receptor for immunoglobulin E (IgE) and is primarily expressed on mature B-cells and follicular dendritic cells, making it an important marker for diagnosing and classifying certain hematologic disorders.

This test is widely used in hematopathology for evaluating lymphoid tissue architecture, identifying specific lymphoma subtypes, and distinguishing between closely related blood cancers. Detecting CD23 helps pathologists classify abnormal lymphoid cells accurately and supports precise diagnosis.

The CD23 marker is especially useful in diagnosing:

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Follicular dendritic cell network assessment
• Certain B-cell lymphomas
• Reactive lymphoid tissue abnormalities

CD23 expression is often used to differentiate CLL/SLL from mantle cell lymphoma, which is an important distinction because treatment approaches differ significantly.

The CD23 IHC test is often performed alongside markers such as CD5, CD20, CD21, Cyclin D1, CD10, and Ki-67 for complete lymphoma characterization and improved diagnostic accuracy.

Benefits of the Test

The CD23 test offers several important clinical benefits:

• Detects CD23 protein expression accurately
• Helps classify lymphoma and leukemia subtypes
• Supports lymphoid tissue evaluation
• Assists in differentiating related blood cancers
• Improves diagnostic precision
• Helps guide treatment planning

This test is essential for accurate hematologic diagnosis.

Why Doctors Recommend This Test

Doctors recommend the CD23 test when lymphoma or leukemia classification is required.

It is commonly advised for:

• Suspected CLL/SLL diagnosis
• Lymph node biopsy evaluation
• Differentiation of B-cell lymphomas
• Follicular dendritic network analysis
• Advanced hematopathology confirmation cases

The results help hematologists and pathologists determine accurate diagnosis and guide effective treatment decisions.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected lymph node biopsy or tissue specimens.

Normal Reporting Time

The usual turnaround time for the CD23 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with enlarged lymph nodes
• Individuals suspected of lymphoma or leukemia
• Patients requiring lymphoid tissue classification
• Cases needing differential lymphoma diagnosis
• Oncology patients requiring precise pathology confirmation

The IHC CD23 test is an important diagnostic tool in hematopathology. It helps classify lymphoid cancers accurately, improves diagnostic confidence, and supports personalized treatment planning for better patient outcomes.